Written and maintained by CASRAI Editorial Board
Last updated
An outpatient infusion center’s general supply list — access, administration, comfort, fluids, and a standard reaction-response cart — is the right starting point for an oncology infusion suite, but it is not the whole list. Oncology infusion adds two things a general infusion checklist does not have to carry: a wider range of venous access devices because a meaningful share of oncology patients arrive with an implanted port or PICC rather than a fresh peripheral stick, and a real, protocol-driven extravasation-response posture because vesicant agents can cause tissue damage if a line fails mid-infusion. Neither of those is a chemotherapy-drug question — they are supply and equipment questions, and they are what this checklist covers. For everything an infusion suite needs regardless of acuity — chair-side comfort, IV fluids, general reaction-cart contents, pump and tubing stocking — see CASRAI’s outpatient infusion center supply checklist; this page is the higher-acuity companion to it, scoped specifically to what an oncology infusion suite needs on top.
Where to source this: LAC (lac.us), CASRAI’s sister medical-supply business under the same operator, stocks several of the core categories on this list directly — IV Catheters (including the smaller-gauge and specialty options oncology access requires), IV Bags for premedication and hydration protocols, and Alcohol Prep Pads for the skin-prep volume a high-access-frequency suite consumes. This is a real, first-party sourcing option, not a third-party referral — procurement teams can browse these categories directly rather than treating LAC as one vendor among many to vet from scratch.
Why oncology infusion is a distinct, higher-acuity stocking case
Two things separate an oncology infusion suite from a general infusion center’s supply profile, and both are supply-and-equipment questions rather than clinical or dosing questions. First, access: many oncology patients receive treatment over months, sometimes years, across repeat cycles, and repeat peripheral sticks on the same veins become progressively harder and more likely to fail — which is why implanted ports and PICC lines are common in this population in a way they are not in most other outpatient infusion settings, and why a suite needs the device range and access supplies to support both peripheral and central access on the same day, sometimes in the same chair. Second, agent class: a portion of the drugs administered in oncology infusion are vesicants, meaning a leak into surrounding tissue (extravasation) can cause real, sometimes serious, local tissue injury — not the drug names or dosing themselves, but the supply-level fact that vesicant risk is real enough that every chair needs standing extravasation-response readiness, checked and dated like the emergency cart, not assembled after the fact. Everything below builds on the general infusion checklist linked above; nothing here repeats what that page already covers well.
Vascular access device range: ports, PICCs, and peripheral access together
An oncology infusion suite needs to support whichever access a given patient already has, which in practice means stocking for three access types side by side rather than defaulting to one. For port access: non-coring (Huber) needles in a range of gauges and lengths to match port depth and infusion type, port-access dressing kits, and extension sets compatible with the port-access needle in use. For PICC lines: PICC-specific dressing-change kits, needleless connectors sized for the line, and clave/cap supplies for between-use maintenance. For peripheral access, when a patient’s veins and treatment plan support it: the same broader gauge range CASRAI’s IV catheter gauge selection guide covers for general infusion, with an emphasis on smaller-gauge catheters and ultrasound-guided-access supplies (sterile probe covers, extra gel) for a population with a meaningfully higher rate of difficult or previously-damaged veins than a general infusion population. A suite that only stocks for peripheral access will regularly turn away or delay patients who present with a port or PICC as their only viable access — the device-range decision is a daily operational one, not an edge case.
Port-access and central-line supply kit contents
Beyond the needle itself, a complete port-access setup needs: chlorhexidine-based skin antisepsis at the access site (CASRAI’s skin antisepsis before injection guide covers product selection and technique in more depth than fits here), a sterile field/drape appropriate to central-access technique, syringes for the required saline flush before and heparin or saline lock flush after infusion per the suite’s protocol, and a labeled log or sticker system documenting needle gauge, access date, and dressing-change date for lines that stay accessed across a visit. Because ports and PICCs represent a bloodstream-adjacent access point held in place for extended periods, dressing integrity and change-interval discipline matter more here than for a same-visit peripheral start — stock enough dressing-change kits that a compromised or non-adherent dressing gets changed immediately rather than stretched to the next scheduled interval.
Extravasation-response readiness
Because a subset of infused agents are vesicants, every oncology infusion chair needs a standing, checked extravasation-response kit — not a supply cabinet down the hall that someone has to remember to visit if a line fails. At the supply level (not the drug-specific treatment level, which is a clinical protocol decision, not a procurement one), a chair-adjacent kit typically includes: a clearly posted, rehearsed extravasation-response protocol; syringes for aspirating residual drug from the line before removal; cold and warm compress supplies (different agent classes call for different thermal response, per the suite’s own protocol); a skin-marking pen to outline the affected area for monitoring; a camera or documentation tool for photographing and tracking the site over time; and whatever antidote or protocol-specific agents the suite’s own clinical policy specifies, stocked and dated per that policy rather than assumed. The Oncology Nursing Society (ONS) publishes chemotherapy and immunotherapy administration safety standards, including extravasation-management guidance, that most infusion suites build their own protocol against — a suite that hasn’t formalized its extravasation kit contents against a named standard should treat that as a gap to close, not an acceptable default. Every chair or bay needs a dated checklist confirming the extravasation kit at that location has been checked, mirroring the general emergency-cart discipline CASRAI’s emergency response cart checklist for outpatient clinics describes — treat that guide’s general reaction-readiness baseline as the floor, and the extravasation kit above as oncology-specific readiness stocked on top of it.
Hazardous-drug handling supplies
Oncology infusion suites that administer chemotherapy or other hazardous drugs carry the same hazardous-drug handling stocking obligation any hazardous-drug-administering infusion setting does: closed-system transfer devices (CSTDs) for connecting and priming hazardous-drug bags and syringes, chemotherapy-rated gloves and gowns (not standard nitrile), spill kits sized and positioned per protocol at every chair, and hazardous-waste containers segregated from standard sharps and trash streams. CASRAI covers the disposal side of this in full in the chemotherapy waste disposal guide (RCRA trace-vs-bulk classification and USP <800> interaction) and the compounding-facility side in the USP 800 cleanroom requirements guide, so neither is repeated here — the point specific to this checklist is that administration-only status (receiving drugs ready-to-hang rather than compounding on site) does not exempt a suite from PPE, spill-response, and waste-segregation stocking during connection, priming, and disconnection at the chair.
Premedication, hydration, and flush supply volume
Oncology infusion protocols routinely bracket the treatment itself with premedication (antiemetics, antihistamines, corticosteroids per protocol) and hydration before and after, which multiplies fluid and small-volume-bag consumption well beyond what a general infusion population needs. CASRAI’s IV bags fluid types and institutional stocking guide covers fluid-type and bag-size selection in full; the oncology-specific point is volume math — a suite running multi-agent premedication protocols ahead of every cycle burns through 50 mL and 100 mL piggyback bags at a materially higher rate than the general infusion par levels in the companion checklist assume, so build oncology-specific par levels from actual premedication-protocol bag counts per cycle, not the general-infusion baseline.
Pump and administration-set considerations for cytotoxic agents
CASRAI’s infusion supplies and pump selection buying guide covers pump selection and tubing compatibility generally and is the right reference for the base equipment decision. The oncology-specific addition: administration sets used for hazardous or cytotoxic agents should be treated as a distinct par-level line from the sets used for non-hazardous infusions, since some sets are matched to specific CSTD connectors or drug-compatibility requirements the pharmacy specifies, and mixing hazardous- and non-hazardous-agent tubing stock invites a connection error the segregation is meant to prevent. Track and reorder the two categories separately, and confirm with the suite’s pharmacy which administration sets are validated for CSTD use before adding a new tubing SKU to either par level.
Building oncology-specific par levels
Start from the general infusion center’s chair-hours-per-week par-level approach (see the companion checklist), then layer oncology-specific adjustments on top: port-access and PICC supply consumption tracked separately from peripheral-access consumption, since the two draw from different SKU pools; extravasation-kit components checked and restocked on a fixed schedule regardless of whether they were used, since a kit that sits untouched for months still needs date-checking; and premedication-driven fluid and bag consumption tracked against actual cycle counts rather than folded into general fluid par levels. A suite that tracks these categories separately, rather than lumping oncology consumption into the general infusion supply line, can see clearly which category is actually driving cost or running short — port-access needles versus peripheral catheters versus extravasation-kit components behave as genuinely different consumption patterns, not variations on one line item.
Frequently asked questions
What does an oncology infusion suite need that a general infusion center checklist doesn’t cover?
Mainly two things: a wider vascular access device range to support implanted ports and PICC lines alongside peripheral access, and a standing, chair-adjacent extravasation-response kit for vesicant-agent risk. Everything else — chair comfort, general reaction-cart contents, fluids, pumps — is shared ground with the general outpatient infusion checklist.
Does every oncology infusion patient need port or PICC access?
No — many patients are infused peripherally, especially early in treatment. But because a meaningful share of oncology patients do have a port or PICC, particularly with repeat-cycle treatment over months, a suite needs the device range and access supplies to support all three access types rather than defaulting to peripheral-only stocking.
What belongs in a chair-adjacent extravasation kit?
At the supply level: a posted response protocol, aspiration syringes, cold and warm compress supplies, a skin-marking pen, a way to document and photograph the site, and whatever protocol-specific agents the suite’s own clinical policy specifies — stocked, dated, and checked on the same schedule as the general emergency cart, not assembled after a reaction occurs.
Is hazardous-drug PPE required even if the suite only administers, never compounds, chemotherapy?
Yes. Administration-only status does not exempt a suite from PPE, spill-response, and waste-segregation stocking during connection, priming, and disconnection at the chair — on-site compounding adds USP <800> facility requirements on top of that, but the baseline handling-supply obligation applies either way.
